Details werden geladen...
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study | The Manila Times
PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced FDA acceptance of a protocol amendment to the ongoing pivotal NANORAY-312 study.
Ähnliche Seiten
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer | The Manila Times
https://www.manilatimes.net/2026/04/13/tmt-newswire/globenewswire/transgene-completes-patient-randomization-in-phase-2-part-of-clinical-trial-evaluating-tg4050-in-the-adjuvant-treatment-of-head-and-neck-cancer/2318775Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembro...
https://www.manilatimes.net/2026/05/05/tmt-newswire/globenewswire/alpha-tau-announces-upcoming-podium-presentation-at-the-ahns-12th-international-conference-on-head-and-neck-cancer-showcasing-study-results-of-alpha-dart-head-and-neck-cancer-combination-with-pembrolizumab/2336170Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study | The Manila Times
https://www.manilatimes.net/2026/03/23/tmt-newswire/pr-newswire/innovent-announces-first-participant-dosed-of-ibi128-tigulixostat-xoi-in-phase-3-clinical-study/2305150Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer | The Manila Times
https://www.manilatimes.net/2026/05/07/tmt-newswire/globenewswire/revolution-medicines-announces-publication-in-new-england-journal-of-medicine-of-phase-12-clinical-data-on-daraxonrasib-in-pancreatic-cancer/2337827Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer | The Manila Times
https://www.manilatimes.net/2026/04/25/tmt-newswire/globenewswire/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-23-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer/2328368